Atellica CH Triglycerides (concentrated)-In vitro diagnostic use in the quantitative measurement of triglycerides in human serum and plasma (lithium heparin, potassium EDTA) using the Atellica CH Analyzer SMN: 11097591
Published September 6, 2023 · Recall initiated: January 27, 2023
Summary
FDA records medical device Class II recall Z-1270-2023, published September 6, 2023 and initiated January 27, 2023. Recalling firm: Siemens Healthcare Diagnostics, Inc.; Status: Ongoing; Reported quantity: 11824 units; Lot: UDI: 00630414596495 All Lots. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Reagent Carryover from LDL Cholesterol Direct (DLDL), Total Protein II (TP), Triglycerides (Trig), and Triglycerides_2 (Trig_2) Impacting Magnesium (Mg) Results
What to do
Voluntary: Firm initiated · Letter
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- Siemens Healthcare Diagnostics, Inc.
- Distributor
- Nationwide Foreign: Country Albania Algeria Argentina Australia Austria Bahrain Bangladesh Belgium Brazil Bulgaria Burkina Faso Canada Chile China Colombia Croatia Cura®ao Czech Republic Denmark Ecuador Egypt Finland France Germany Greece Guadeloupe Hong Kong Hungary India Ireland Israel Italy Japan Kuwait Libya Malaysia Mexico Netherlands New Zealand Norway Oman Pakistan Paraguay Peru Philippines Poland Portugal Qatar Republic Korea Romania Saudi Arabia Serbia Singapore Slovakia Slovenia South Africa Spain Sweden Switzerland Taiwan, Province of China Thailand Ukraine United Arab Emirates United Kingdom Great Britain Uruguay Vatikancity Vietnam
- Lot
- UDI: 00630414596495 All Lots
- Risk classification
- Class II
- Area (FDA)
- device
- Country
- United States
Related recalls
- FDAAtellica CH Revised C-Reactive Protein (RCRP); Siemens Material Number (SMN): 11537223;October 7, 2026
- FDABeckman Coulter, Emit 2000 Quinidine Assay REF: OSR4Q229 Contents: R1: 2 x 23 mL;R2 2x13 mLAugust 26, 2026
- FDASyva EMIT 2000 Quinidine Assay REF: 4Q019UL Contents: 1x28 mL, 1x14mLAugust 26, 2026
- FDASyva Emit tox Serum Tricyclic Antidepressant Calibrator/Controls SMN 10445390 Catalog No. 7C219ULAugust 12, 2026
- FDAMehlenbacher's Taffy, 1.25 oz per piece, 36 pieces/box, cello wrapped. Peanut butter cup, UPC 022099174080.September 6, 2023
- FDAAtellica CH Gamma-Glutamyl Transferase-IIn vitro diagnostic use in the quantitative determination ofSeptember 6, 2023
Questions about this recall
Was Atellica CH Triglycerides (concentrated)-In vitro diagnostic use in the quantitative measurement of triglycerides in human serum and plasma (lithium heparin, potassium EDTA) using the Atellica CH Analyzer SMN: 11097591 recalled?
Yes. FDA published recall Z-1270-2023 on September 6, 2023. Reported hazard: Reagent Carryover from LDL Cholesterol Direct (DLDL), Total Protein II (TP), Triglycerides (Trig), and Triglycerides_2 (Trig_2) Impacting Magnesium (Mg) Results
What should I do if I have this product?
Voluntary: Firm initiated · Letter